NCT03581292 2026-04-13
Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations
National Cancer Institute (NCI)
Phase 2 Active not recruiting
National Cancer Institute (NCI)
BeiGene
National Cancer Institute (NCI)
Children's Oncology Group
Alliance for Clinical Trials in Oncology
Merck Sharp & Dohme LLC